RT Journal Article
T1 Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project.
A1 Pose, Antonio
A1 Almenar, Luis
A1 Gavira, Juan José
A1 López-Granados, Amador
A1 Blasco, Teresa
A1 Delgado, Juan
A1 Aramburu, Oscar
A1 Rodríguez, Avelino
A1 Manzano, Luis
A1 Manito, Nicolás
K1 Congestive heart failure
K1 Diuresis
K1 Hyponatraemia
K1 Tolvaptan
K1 Vasopressin type 2 receptors
AB Hyponatraemia is an electrolyte disorder that occurs in advanced congestive heart failure (HF) and worsens prognosis. We explored the usefulness of tolvaptan, which has shown promising results in the treatment of this condition. This study is based on a retrospective national registry (2011-15) of patients hospitalized with refractory HF and hyponatraemia who agreed to receive tolvaptan when standard treatment was ineffective. The benefit of tolvaptan was analysed according to the following criteria: normalization ([Na+] ≥ 135 mmol/L) or increased sodium levels [Na+] ≥ 4 mEq/L on completion of treatment, and increase in urine output by 300 or 500 mL at 48 h. Factors associated with tolvaptan benefit were explored. A total of 241 patients were included, 53.9% of whom had ejection fraction  An increase in sodium levels and/or improvement in urine output was observed in patients admitted for HF and refractory hyponatraemia under tolvaptan treatment. Tolvaptan may be useful in this setting, in which no effective proven alternatives are available.
SN 2055-5822
YR 2017
FD 2017-01-19
LK https://hdl.handle.net/10668/24774
UL https://hdl.handle.net/10668/24774
LA en
DS RISalud
RD Apr 8, 2025